ImmusanT

ImmusanT is working to help sufferers of celiac disease. We are constantly inspired by people in need. Read some of their comments and stories >

Our principal aim is to develop a treatment designed to replace a gluten-free diet for celiac disease sufferers. Our scientists are world leaders in celiac disease research and have developed robust science and patents, and a drug approved for entry into human trials. More >

what is celiac disease?

Celiac disease is a condition that damages the lining of the small intestine and prevents it from absorbing parts of food that are important for staying healthy. The damage is due to a reaction to eating gluten, which is found in wheat, barley, rye, and possibly oats.

The disease affects over 3 million (1 in 133) Americans.(ref. 17) Read More >

news

Dec 13, 2011 - ImmusanT Raises $20 Million in Series A Financing Read More >

Dec 3, 2011 - Australian Media Coverage of ImmusanT Read More >

Oct 27, 2011 - 10 Promising Therapeutic Vaccines Read More >

pipeline

We are developing the peptide-based therapeutic vaccine, Nexvax2®, that is based upon ground-breaking research. Preclinical development including proof of concept studies and Phase I clinical trial are complete. Clinical development of Nexvax2® in patients with celiac disease is advancing with PPDi (Pharmaceutical Product Development) as a partner. Pipeline >